Cargando…
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
BACKGROUND: The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether azithromycin is effective in reducing hospital admission in patients with mild...
Autores principales: | Hinks, Timothy S C, Cureton, Lucy, Knight, Ruth, Wang, Ariel, Cane, Jennifer L, Barber, Vicki S, Black, Joanna, Dutton, Susan J, Melhorn, James, Jabeen, Maisha, Moss, Phil, Garlapati, Rajendar, Baron, Tanya, Johnson, Graham, Cantle, Fleur, Clarke, David, Elkhodair, Samer, Underwood, Jonathan, Lasserson, Daniel, Pavord, Ian D, Morgan, Sophie, Richards, Duncan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270523/ https://www.ncbi.nlm.nih.gov/pubmed/34252378 http://dx.doi.org/10.1016/S2213-2600(21)00263-0 |
Ejemplares similares
-
A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial
por: Hinks, Timothy S. C., et al.
Publicado: (2020) -
Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
por: Couillard, Simon, et al.
Publicado: (2022) -
Recovery of Breakthrough Asthma Attacks Treated With Oral Steroids While on Monoclonal Antibody Therapy: Protocol for a Prospective Observational Study (BOOST)
por: Howell, Imran, et al.
Publicado: (2023) -
Azithromycin in viral infections
por: Oliver, Madeleine E., et al.
Publicado: (2020) -
MAIT cells and the microbiome
por: Jabeen, Maisha F., et al.
Publicado: (2023)